Skip to main content

Table 1 Pharmacokinetic parameters for pantoprazole, rabeprazole, and omeprazole under fasting and fed conditions. Among 71 volunteers receiving omeprazole, 35 were the same subjects. Data are expressed as mean ± standard deviation. *p ≤ 0.05 vs. men

From: Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole

  n AUC0-∞ (ng·h/ml) Cmax (ng/ml) Tmax (h) t1/2 (h) Vd/F (l/kg) Cl/F (L/h·kg) Ke
Pantoprazole (n = 81)
Fast 36 6951.4 ± 3293.2 2779.1 ± 861.6 3.0 ± 0.8 1.3 ± 0.6 0.17 ± 0.03 0.11 ± 0.04 0.61 ± 0.21
  Men 18 6584.5 ± 3832.8 2316.4 ± 580.9 3.1 ± 0.8 1.5 ± 0.7 0.18 ± 0.03 0.11 ± 0.03 0.56 ± 0.23
  Women 18 7318.4 ± 2711.6 3241.8 ± 858.8 2.9 ± 0.8 1.1 ± 0.3 0.16 ± 0.03 0.11 ± 0.05 0.65 ± 0.18
Fed 45 4633.5 ± 2022.7 2646.2 ± 603.1 7.0 ± 3.0 1.3 ± 0.6 0.26 ± 0.10 0.16 ± 0.06 0.63 ± 0.21
  Men 23 4607.8 ± 2265.1 2590.7 ± 601.2 5.6 ± 1.1 1.3 ± 0.5 0.25 ± 0.08 0.15 ± 0.07 0.61 ± 0.23
  Women 22 4660.4 ± 1787.8 2704.2 ± 613.6 8.4 ± 3.7* 1.2 ± 0.7 0.28 ± 0.12 0.17 ± 0.05 0.65 ± 0.19
Fed vs. Fast
ratio; 90% CI; p value
65.6; 55.7–77.2
p = 0.0001
93.7; 85.5–102.7
p = 0.2412
227.2; 203.2–254.1
p = 0.0001
95.3; 82.8–109.8
p = 0.5749
147.1; 134.3–161.0
p = 0.0001
151.0; 128.7–177.2
p = 0.0001
104.9; 91.1–120.7
p = 0.5749
Rabeprazole (n = 69)
Fast 35 971.9 ± 361.2 556.4 ± 176.2 3.7 ± 0.9 1.3 ± 0.5 0.60 ± 0.17 0.35 ± 0.11 0.60 ± 0.20
  Men 18 836.3 ± 313.0 479.1 ± 139.7 3.6 ± 0.9 1.2 ± 0.5 0.55 ± 0.11 0.35 ± 0.13 0.64 ± 0.20
  Women 17 1115.5 ± 361.4 638.3 ± 177.2 3.7 ± 0.9 1.4 ± 0.5 0.65 ± 0.20 0.35 ± 0.10 0.56 ± 0.20
Fed 34 1047.3 ± 382.3 675.8 ± 218.8 7.2 ± 2.6 2.2 ± 1.3 0.91 ± 0.45 0.34 ± 0.18 0.42 ± 0.22
  Men 19 1045.8 ± 361.49 634.6 ± 144.8 6.9 ± 3.0 2.3 ± 1.3 0.91 ± 0.52 0.31 ± 0.18 0.38 ± 0.17
  Women 15 1049.2 ± 420.3 727.9 ± 284.0 7.6 ± 2.0 2.0 ± 1.3 0.92 ± 0.37 0.38 ± 0.18 0.48 ± 0.27
Fed vs. Fast
ratio; 90% CI; p value
106.7; 91.3–124.8
p = 0.4886
121.3; 106.9–137.6
p = 0.0132
191.5; 172.2–212.9
p = 0.0001
153.1; 126.9–184.7
p = 0.0003
144.3; 125.6–165.9
p = 0.0001
93.1; 79.5–109.1
p = 0.4531
65.3; 54.1–78.8
p = 0.0003
Omeprazole (n = 36)
Fast 35 2190.8 ± 2011.5 930.9 ± 434.6 2.0 ± 0.7 1.1 ± 0.6 0.64 ± 0.34 0.53 ± 0.38 0.76 ± 0.29
  Men 17 2375.9 ± 2480.1 858.8 ± 432.6 2.1 ± 0.7 1.3 ± 0.8 0.65 ± 0.38 0.50 ± 0.44 0.70 ± 0.29
  Women 18 2016.0 ± 1495.4 999.1 ± 437.7 1.9 ± 0.6 1.0 ± 0.4 0.63 ± 0.31 0.56 ± 0.34 0.82 ± 0.29
Fed 36# 1928.3 ± 1878.5 682.6 ± 394.1 4.9 ± 1.1 1.3 ± 0.6 1.02 ± 1.07 0.64 ± 0.55 0.67 ± 0.32
  Men 18 2135.8 ± 2282.7 725.0 ± 447.6 4.5 ± 0.9 1.3 ± 0.7 0.75 ± 0.52 0.57 ± 0.49 0.69 ± 0.35
  Women 18 1720.9 ± 1402.0 640.2 ± 640.1 5.4 ± 1.0 1.3 ± 0.5 1.30 ± 1.38 0.73 ± 0.61 0.65 ± 0.30
Fed vs. Fast
ratio; 90% CI; p value
86.2; 81.2–91.6
p = 0.0002
63.0; 55.0–72.2
p = 0.0001
262.5; 232.6–296.2
p = 0.0001
117.6; 105.6–130.9
p = 0.0156
136.1; 105.6–130.9
p = 0.0029
116.1; 108.7–124.1
p = 0.0006
85.0; 76.4–94.7
p = 0.0156
  1. #35 of the subjects participated in both fast and fed omeprazole clinical trials